Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974284 · ClinicalTrials.gov registry record · NA
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01974284: Clinical Trial NA study, sponsored by Yale University.
NCT01974284 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01974284, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.
Primary Outcome
Primary endpoint of the study consists of the oncological outcome, which includes the disease-free status of the patients.
Interventions
- DRUG percutaneous ethanol ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-03 |
| Est. Completion | 2017-06-29 |
| Phase | NA |
Why NCT01974284 stopped before completion
NCT01974284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which percutaneous ethanol ablation is the first listed.
NCT01974284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01974284 about?
NCT01974284 is a clinical study titled "Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma". We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.
What is the current status of trial NCT01974284?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2014-03. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01974284?
The interventions under investigation include: percutaneous ethanol ablation (DRUG).
Who is sponsoring clinical trial NCT01974284?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01974284's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia